APA
Lahoz, Carlos & Cárdenas Valladolid, Juan & Salinero Fort, Miguel Ángel & Mostaza, José María .Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain.
ISO 690
Lahoz, Carlos & Cárdenas Valladolid, Juan & Salinero Fort, Miguel Ángel & Mostaza, José María. Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain.
https://hdl.handle.net/20.500.12080/25305
dc.contributor.author |
Lahoz, Carlos |
|
dc.contributor.author |
Cárdenas Valladolid, Juan
|
|
dc.contributor.author |
Salinero Fort, Miguel Ángel |
|
dc.contributor.author |
Mostaza, José María |
|
dc.date.accessioned |
2021-08-30T13:53:47Z |
|
dc.date.available |
2021-08-30T13:53:47Z |
|
dc.date.created |
2021-07-27 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12080/25305 |
|
dc.description.abstract |
Background The role of statins in the management of dyslipidemia in elderly patients with different cardiovascular risks
remains unclear.
Objective To study use of statins and associated factors in subjects aged 90 or over in the Community of Madrid, Spain.
Methods Observational, cross-sectional study that included all people aged 90 or more residing in the Community of
Madrid as of December 31, 2015. The clinical information was obtained from the database that contains the electronic
medical records collected by family doctors in primary care. Comorbidity data are collected according to the International
Classification of Primary Care, Second Edition (ICPC-2).
Results The study population comprised 59,423 subjects, with a mean age of 93.3 (2.5) years (25.8% males). Slightly more
than one quarter of the population (28.2%) was in treatment with statins, 21.9% were in primary prevention, and 48.1% in
secondary prevention. The multivariate analysis revealed the factors independently associated with statin treatment to be
younger age, not being institutionalized, a higher Barthel score, a lower Charlson score, a higher body mass index, and a
history of diabetes, dyslipidemia, chronic kidney disease, and cardiovascular disease.
Conclusions A significant percentage of nonagenarians¿mainly less frail patients with more comorbidities¿in the Community
of Madrid receive statin treatment. No clear efficacy has been demonstrated in reducing cardiovascular events in an
age group with such a short life expectancy.
Keywords Nonagenarians · Statins · Associated factors |
es_ES |
dc.format |
application/pdf |
es_ES |
dc.language |
eng |
es_ES |
dc.rights |
CC-BY |
es_ES |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/deed.es |
es_ES |
dc.title |
Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
es_ES |
dc.type |
info:eu-repo/semantics/article |
es_ES |
dc.rights.accessrights |
info:eu-repo/semantics/openAccess |
es_ES |
dc.identifier.location |
N/A |
es_ES |